4//SEC Filing
Aurentz Vincent 4
Accession 0001415889-24-028024
CIK 0001832168other
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 7:22 PM ET
Size
16.2 KB
Accession
0001415889-24-028024
Insider Transaction Report
Form 4
Aurentz Vincent
Director
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2024-12-02−12,367→ 0 totalExercise: $4.40Exp: 2032-05-23→ Common Stock (12,367 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-12-02−12,367→ 0 totalExercise: $9.10Exp: 2031-09-13→ Common Stock (12,367 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-12-02−12,500→ 0 totalExercise: $7.06Exp: 2033-05-24→ Common Stock (12,500 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-12-02−7,214→ 0 totalExercise: $9.10Exp: 2031-09-13→ Common Stock (7,214 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-12-02−22,500→ 0 totalExercise: $18.94Exp: 2034-05-22→ Common Stock (22,500 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
- [F2]On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Documents
Issuer
Longboard Pharmaceuticals, Inc.
CIK 0001832168
Entity typeother
Related Parties
1- filerCIK 0001657494
Filing Metadata
- Form type
- 4
- Filed
- Dec 1, 7:00 PM ET
- Accepted
- Dec 2, 7:22 PM ET
- Size
- 16.2 KB